Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.
Exavir Therapeutics has raised $3.0M in total funding. The most recent round was Grant. The last funding was announced in August 2023.
Exavir Therapeutics's investors include Gilead Sciences, AlleyCorp, National Institute of Allergy and Infectious Diseases.
Exavir Therapeutics is headquartered in San Francisco, United States.
Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections.
Exavir Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Exavir Therapeutics — Funding & Investors." VCBacked, August 22, 2023, https://www.vcbacked.co/company/exavir-therapeutics. Accessed September 29, 2026.
VCBacked. (2023). Exavir Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/exavir-therapeutics
{{cite web |title=Exavir Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/exavir-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated